skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Reparixin (Code C66515)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Reparixin

Definition: An orally available inhibitor of CXC chemokine receptor types 1 (CXCR1) and 2 (CXCR2), with potential antineoplastic activity. Upon administration, reparixin allosterically binds to CXCR1 and prevents CXCR1 activation by its ligand interleukin 8 (IL-8 or CXCL8). This may cause cancer stem cell (CSC) apoptosis and may inhibit tumor cell progression and metastasis. CXCR1, overexpressed on CSCs, plays a key role in CSC survival and the ability of CSC to self-renew; it is also linked to tumor resistance to chemotherapy. Inhibition of the IL-8/CXCR1 interaction also potentiates the cytotoxic effect of chemotherapeutic agents. In addition, reparixin inhibits CXCR2 activation and may reduce both neutrophil recruitment and vascular permeability during inflammation or injury.

Display Name: Reparixin

Label: Reparixin

NCI Thesaurus Code: C66515 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1506747  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Benzeneacetamide, Alpha-methyl-4-(2-methylpropyl)-N- (methylsulfonyl)- (alphaR)-
DF 1681Y

External Source Codes: 
CAS Registry Number 266359-83-5 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 750172
PDQ Open Trial Search ID 750172 (check for NCI PDQ open clinical trial info)
UMLS CUI C1506747

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C14H21NO3S
code C66515
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Reparixin
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom